121 related articles for article (PubMed ID: 21550672)
1. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients.
Skarica M; Eckstein C; Whartenby KA; Calabresi PA
J Neuroimmunol; 2011 Jun; 235(1-2):70-6. PubMed ID: 21550672
[TBL] [Abstract][Full Text] [Related]
2. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
3. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer A; Wipfler P; Einhaeupl M; Pilz G; Oppermann K; Hitzl W; Afazel S; Haschke-Becher E; Strasser P; Trinka E; Kraus J
J Neuroimmunol; 2011 May; 234(1-2):148-54. PubMed ID: 21450349
[TBL] [Abstract][Full Text] [Related]
5. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
Putzki N; Baranwal MK; Tettenborn B; Limmroth V; Kreuzfelder E
Eur Neurol; 2010; 63(5):311-7. PubMed ID: 20453514
[TBL] [Abstract][Full Text] [Related]
6. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab effects on immune cell responses in multiple sclerosis.
Niino M; Bodner C; Simard ML; Alatab S; Gano D; Kim HJ; Trigueiro M; Racicot D; Guérette C; Antel JP; Fournier A; Grand'Maison F; Bar-Or A
Ann Neurol; 2006 May; 59(5):748-54. PubMed ID: 16634035
[TBL] [Abstract][Full Text] [Related]
8. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
Stüve O
J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
[TBL] [Abstract][Full Text] [Related]
9. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
del Pilar Martin M; Cravens PD; Winger R; Frohman EM; Racke MK; Eagar TN; Zamvil SS; Weber MS; Hemmer B; Karandikar NJ; Kleinschmidt-DeMasters BK; Stüve O
Arch Neurol; 2008 Dec; 65(12):1596-603. PubMed ID: 18852339
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
Krumbholz M; Meinl I; Kümpfel T; Hohlfeld R; Meinl E
Neurology; 2008 Oct; 71(17):1350-4. PubMed ID: 18936427
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I
Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for multiple sclerosis.
Ransohoff RM
N Engl J Med; 2007 Jun; 356(25):2622-9. PubMed ID: 17582072
[No Abstract] [Full Text] [Related]
15. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.
Lindberg RL; Achtnichts L; Hoffmann F; Kuhle J; Kappos L
J Neuroimmunol; 2008 Feb; 194(1-2):153-64. PubMed ID: 18178259
[TBL] [Abstract][Full Text] [Related]
16. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
[TBL] [Abstract][Full Text] [Related]
18. The regulatory role of natural killer cells in multiple sclerosis.
Takahashi K; Aranami T; Endoh M; Miyake S; Yamamura T
Brain; 2004 Sep; 127(Pt 9):1917-27. PubMed ID: 15229129
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab treatment reduces endothelial activity in MS patients.
Millonig A; Hegen H; Di Pauli F; Ehling R; Gneiss C; Hoelzl M; Künz B; Lutterotti A; Rudzki D; Berger T; Reindl M; Deisenhammer F
J Neuroimmunol; 2010 Oct; 227(1-2):190-4. PubMed ID: 20739072
[TBL] [Abstract][Full Text] [Related]
20. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
Rice GP; Hartung HP; Calabresi PA
Neurology; 2005 Apr; 64(8):1336-42. PubMed ID: 15851719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
